Published in final edited form as:

J Med Chem. 2015 February 12; 58(3): 1215–1227. doi:10.1021/jm501449u.

Antibacterial Drug Leads: DNA and Enzyme Multi-Targeting

Wei Zhu¹, Yang Wang¹, Kai Li¹, Jian Gao², Chun-Hsiang Huang², Chun-Chi Chen², Tzu-Ping Ko³, Yonghui Zhang¹, Rey-Ting Guo², and Eric Oldfield^{1,*}

¹Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States

²Industrial Enzymes National Engineering Laboratory, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China

³Institute of Biological Chemistry, Academia Sinica, Taipei 11529, Taiwan

Abstract

We report the results of an investigation of the activity of a series of amidine and bisamidine compounds against *Staphylococcus aureus* and *Escherichia coli*. The most active compounds bound to an AT-rich DNA dodecamer (CGCGAATTCGCG)₂, and using DSC were found to increase the melting transition by up to 24 °C. Several compounds also inhibited undecaprenyl diphosphate synthase (UPPS) with IC₅₀ values of 100–500 nM and we found good correlations ($R^2 = 0.89$, *S. aureus*; $R^2 = 0.79$, *E. coli*) between experimental and predicted cell growth inhibition by using DNA T_m and UPPS IC₅₀ experimental results together with 1 computed descriptor. We also solved the structures of three bisamidines binding to DNA as well as three UPPS structures. Overall, the results are of general interest in the context of the development of resistance-resistant antibiotics that involve multi-targeting.

Keywords

Drug discovery; Protein structure; DNA minor groove binder; Undecaprenyl diphosphate synthase

*Corresponding Author: eoldfiel@illinois.edu. Tel: 217-244-0997.

ASSOCIATED CONTENT

Supporting Information

Supporting Information Available: additional Tables and Figures illustrating statistics for the correlations, ligand electron density maps, protein/DNA-ligand interactions. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Accession Codes

The atomic coordinates and structure factors (PDB ID codes 4U8A, 4U8B, 4U8C, 4U82, 3WYI, and 3WYJ) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (<http://www.rcsb.org/>).

Author Contributions

W.Z. and E.O. designed research; Y.W., K.L. and Y.Z. synthesized compounds; W.Z. performed enzymatic and cell growth inhibition assays and DSC experiments; W.Z., J.G., C.-H.H., C.-C.C., T.-P.K. and R.-T.G. performed crystallographic experiments; W.Z. and E.O. analyzed data. W.Z. and E.O. wrote the paper.

The authors declare no competing financial interest.

Introduction

There is currently a dearth of new antibiotics being introduced with both the United States Centers for Disease Control and Prevention¹ as well as the World Health Organization,² and others,³ warning of the seriousness of the development of widespread antibiotic resistance. The problem is a multi-faceted one with many factors such as use of antibiotics in feedstocks, unnecessary prescriptions, efflux pumps, and drug modifications all contributing to the problem. In addition, of course, random mutations in a target can occur, rendering a drug ineffective. One approach to ameliorate the latter problem is the use of combination therapies and these are the norm for malaria, HIV/AIDS, tuberculosis, as well as cancer therapeutics. While the development of just one new drug is a daunting prospect, the development of two new drugs (with new targets/mechanisms of action) will be even more challenging, hence the interest is new leads that act by multiple-targeting: one drug (drug lead) but two (or more) targets—an approach that can improve efficacy as well as decrease the likelihood of resistance developing. In our lab, we recently used computational screening to try and find novel inhibitors of two anti-bacterial drug targets, farnesyl diphosphate synthase (FPPS)^{4,5} and undecaprenyl diphosphate synthase (UPPS),⁶ that are involved in bacterial cell wall biosynthesis (and are not the targets of any currently FDA-approved anti-infective drugs). Inhibiting either of these targets would be of interest since it could lead to “resistance reversal” in e.g. methicillin or vancomycin resistant bacteria (in a combination therapy), with UPPS inhibition being of particular interest since humans do not possess a UPPS gene. We found from our *in silico* and *in vitro* work^{5,6} that the bisamidine **1** (BPH-1358) was an inhibitor of both FPPS (IC₅₀ ~2 μ M) as well as UPPS (IC₅₀ ~100 nM) and was active against *S. aureus* *in vitro* (MIC ~250 ng/mL) and *in vivo* (20/20 mice survived in an i.p. infection model with a MRSA strain) and in addition, **1** (Scheme 1) acted synergistically with methicillin (with a fractional inhibitory concentration index, FICI = 0.25).⁶

1 is, as noted above, a bisamidine (or a diamidine) and somewhat related compounds (derived from synthalin, **2**) have been developed as anti-infectives since ~1937.⁷ For example, pentamidine (**3**) has been used against trypanosomatid infections and is still used against *Pneumocystis jirovecii* pneumonia in HIV/AIDS patients. It is, however, a rather toxic compound—despite being on the World Health Organization's List of Essential Medicines. In later work (beginning in 1960), the A. Wander Company⁸ developed large numbers of again generally related compounds, bisamidines such as **4**, primarily as anti-leukemia drug leads, but some were also found to have activity against *Trypanosoma brucei*, *T. congolense*, the apicomplexan *Babesia rodaini*, as well as the bacterium *Mycobacterium tuberculosis*.⁸ Other bisamidines were later developed and found to have promising activity against several other bacteria⁹ and **5** and related compounds (see ¹⁰ for a historical perspective) have been in clinical trials for human African trypanosomiasis. In many cases, the mechanism of action (or target) is not completely clear and, interestingly, it has been found with for example **6** and **7**, that DNA synthesis as well as cell wall biosynthesis are targeted (based on macromolecular labeling studies).^{11–13} In other cases, mitochondrial function is disrupted.¹⁴ One possible inference from these results is that bisamidines may often have more than one target, with so-called “multi-target” inhibitors being of interest

because they could be less prone to the development of spontaneous resistance due to target mutations, with multi-target inhibition¹⁵ being thought to be one of the main reasons that some antibiotics have been relatively successful in mono-therapy.¹⁶

The bisamidines **6**, **7** and several related compounds have also been shown to bind to bacterial DNA (as observed by fluorescence – the DNA-bound ligands are highly fluorescent) and, more specifically, AT-rich DNA^{11,12,17} in which hydrogen-bonding between the ligand and DNA bases can occur.¹⁸ What is interesting here is that, in addition to these bisamidines binding to bacterial DNA, DNA-binding is also the proposed mechanism of action of several of the bisamidines that have been developed as anti-trypansomatid drug leads (that reached clinical trials) where it is kinetoplast DNA (k-DNA) that is targeted.¹⁷ DNA minor groove binders have also been developed to target a broad range of fungal and bacterial pathogens including *Clostridium difficile*,¹⁹ so the possibility exists that it might be possible to develop compounds that target both DNA as well as a pathogen enzyme target (e.g. UPPS or FPPS), improving selectivity.

In this work, we synthesized a range of amidines and bisamidines and tested them, as well as other known bisamidines, for their binding to (or inhibition of) *E. coli* UPPS, *S. aureus* UPPS, and an AT-rich DNA-duplex (CGCGAATTCGCG)₂ and correlated these results with their effects on *S. aureus* and *E. coli* cell growth. In some cases we found both DNA minor groove binding as well as UPPS inhibition, leading to predictive models of cell growth inhibition. We also solved three X-ray structures of some of the leads bound to the DNA dodecamer duplex, in addition to determining three UPPS X-ray structures.

Results and Discussion

We investigated the compounds shown in Figure 1 for their effects on enzyme (*E. coli* UPPS, *S. aureus* UPPS) inhibition, *E. coli* and *S. aureus* cell growth inhibition, and on the folded-unfolded transition of the AT-rich DNA dodecamer duplex, (CGCGAATTCGCG)₂. Compounds **6–8** have known anti-bacterial activity and were discovered or developed by Microbiotix (Worcester, MA) from a DTP/NCI (Developmental Therapeutics Program/ National Cancer Institute) screening library (**6** = MBX-1162; **7** = MBX-1066 = NSC-317881; **8** = MBX-1090 = NSC-317880); **9** is the anti-bacterial netropsin; **1** is the bisamidine (NSC 50460) reported previously^{5,6} to be a potent UPPS, FPPS inhibitor active against *S. aureus* *in vitro* and *in vivo*. Compounds **10–13**, **16–17** are all analogs of **1** or **10** containing various side-chain or backbone modifications (see Experimental Section for synthesis and characterization); **14** is a Wander A.G. compound (NSC-60340); **3** is pentamidine; **15** is an amidine based on the synthetic antimicrobial **18**²⁰ (which contains the “cationic-hydrophobic-cationic” motif found in the bisamidines). Compound **19** is a very potent UPPS inhibitor (IC₅₀ ~400 nM), but is not expected to bind to DNA (since it is highly anionic).

Enzyme Inhibition

We first tested all 16 compounds against UPPS from *E. coli* and *S. aureus*. Results are shown in Table 1. The compounds are rank-ordered by their T_m values, the strongest DNA-binder being at the top of the Table. As can be seen in Table 1, **1** in the most potent

inhibitor of both *E. coli* UPPS (EcUPPS) as well as *S. aureus* UPPS (SaUPPS) with an $IC_{50} = 110$ nM. The tetraphosphonate **19** is also a potent UPPS inhibitor with an $IC_{50} \sim 400$ nM against both enzymes. The bisindole **6** likewise has potent activity against both enzymes and **7** (the same structure as **6** except for the replacement of the 6-membered bisamidine ring by a 5-membered ring) has good activity against EcUPPS ($IC_{50} = 360$ nM) but less ($IC_{50} = 1.7$ μ M) against SaUPPS. Several other compounds (**13**, **18**) have low or sub-micromolar activity against SaUPPS, but are less active against EcUPPS. Clearly, the overall most active compounds are **1**, **6**, **7** and **19**. Compounds **1**, **6**, **7** are bisamidines while **19** is a tetraphosphonate. With the analogs of **1**, replacement of the 5-membered ring by a 6 membered ring reduced UPPS inhibition activity by 50 fold (Table 1) and replacement of the amide by a thioamide (**1** $\rightarrow$ **11**) reduced activity by a similar amount. Other side-chain modifications all greatly reduced activity.

Cell growth inhibition results

With these results on UPPS inhibition in hand, we next investigated the activity of all 16 compounds against two bacteria, the Gram-negative *E. coli*, and the Gram-positive, *S. aureus*. Cell growth inhibition results are shown in Table 1. As can be seen in Table 1, there are 4 compounds with <1 μ M activity against both organisms **1**, **6**, **7**, and **10**, with similar results for **6–8** having been reported previously.^{9,11,12,17} In most cases, these four compounds have good activity against UPPS, the exception being **10** (where UPPS IC_{50} values are ~ 5 μ M). However, the potent UPPS inhibitor **19** had no cell activity, presumably because it has poor permeability and in previous work²¹ we found only one related (bisphosphonate) inhibitor having activity ($EC_{50} = 33$ μ M), against *E. coli*. These results appear to be in accord with the idea that UPPS could be a target for the most potent cell growth inhibitors (some of which have been shown to inhibit cell wall biosynthesis). There is, however, only a very poor overall correlation between enzyme pIC_{50} ($= -\log_{10} IC_{50}$) and cell growth inhibition pEC_{50} values with $R^2 = 0.25$, p -value = 0.05 for *E. coli*/EcUPPS, and $R^2 = 0.16$, p -value = 0.12 for the *S. aureus*/SaUPPS results (Supporting Information Table S1). It thus seemed that there might be another, more important target, DNA, since as noted in the Introduction, in other work it has been shown that bisamidines bind to AT-rich DNA, both in bacteria¹¹ as well as to kinetoplast DNA, in trypanosomatid parasites such as *T. brucei*.¹⁷

DNA binding: calorimetry and crystallography

We thus next investigated the binding of the 16 compounds shown in Table 1 to a DNA dodecamer duplex containing an AT-rich central domain: (CGCGAATTCGCG)₂, used previously to study the binding of Hoechst 33258,²² propamidine²³ (pentamidine but with a C₃ linker) and other ammonium compounds.²⁴ We used differential scanning calorimetry (DSC) to study the DNA-ligand interaction, and DSC thermograms for all 16 compounds are shown in Figure 2 (the results for the compounds having the largest T_m values being shown at top left).

The changes in the DNA thermal unfolding temperatures, T_m (where T_m is the maximum in the C_p vs. T thermogram) are given in Table 1 and the DSC thermogram results are shown in Figure 2, ranked according to their T_m values. In most cases there was a single

component observed, although in several instances there were two components (folded + unfolded), due presumably to solubility/incomplete mixing deficiencies. The two strongest binding ligands were **6** ($T_m = 24\text{ }^{\circ}\text{C}$) and **8** ($T_m = 20\text{ }^{\circ}\text{C}$), followed by **7** ($T_m = 16\text{ }^{\circ}\text{C}$) and **9** (netropsin, $T_m = 16\text{ }^{\circ}\text{C}$). **1**, the 5 membered biphenyl bisamidine had $T_m = 11\text{ }^{\circ}\text{C}$, essentially the same as the 6-membered ring analog **10** ($T_m = 10\text{ }^{\circ}\text{C}$). The thioamide analog of **1**, **11**, had worse binding ($T_m = 7.1\text{ }^{\circ}\text{C}$). Pentamidine (**3**) was also a poor binder ($T_m = 2.7\text{ }^{\circ}\text{C}$). Clearly, for most potent binding, the presence of a bisamidine is required, together with, perhaps, central groups that might H-bond to the DNA bases. What is particularly interesting about these DSC results is that the most potent DNA binders are also some of the most the potent UPPS inhibitors, as well as the most potent cell growth inhibitors, suggesting, perhaps, dual target inhibition.

To see how some of the bisamidines actually bound to the d(CGCGAATTCGCG)₂ duplex, we used X-ray crystallography, co-crystallizing the DNA-ligand complexes as described in the Experimental Section. Full crystallographic data acquisition and structure refinement details are given in Table 2. Ligand electron density maps and ligand-protein interactions are given in Supporting Information Figures S1–4.

As can be seen in Figure 3, **1**, **6** and **10** all bound to the minor groove of the AT-rich dodecamer, and in each case there are H-bond contacts between the nitrogen atoms in the ligands, either in the amidine ring, amide bond (**1** and **10**) or in the indole group (**6**), with the bases in the DNA minor groove. Although there are only 3 structures, more interactions correlate with stronger binding, that is, a bigger T_m : **6** has 6 H-bond contacts and a $T_m = 24\text{ }^{\circ}\text{C}$; **1** and **10** have only 3–4 interactions and a $T_m \sim 10\text{ }^{\circ}\text{C}$, Figure 3 and Supporting Information Figures S2–4.

Models for cell growth inhibition

These DSC T_m results now enable us to test the hypothesis that the cell-based activity we see could be due to DNA binding, to UPPS binding, or to both DNA as well as UPPS binding. We first used a simple heat-map approach, Figure 4A, from which it can be seen that *S. aureus* cell growth inhibition can be quite potent and is most strongly correlated with T_m (both in red/orange), with a weaker correlation with SaUPPS inhibition (Figure 4A). The trends are similar with *E. coli* (Figure 4A). The quantitative correlation between cell growth inhibition and either pIC₅₀ (UPPS) or DNA T_m results are however poor, as shown in Table S1, varying from 0.16 to 0.62. We thus next employed the basic approach derived earlier²⁵ in which we used Eqn. 1:

$$\text{pEC}_{50}(\text{cell}) = a \bullet A + b \bullet B + c \bullet C + d \quad (\text{Eqn. 1})$$

where in this case A = UPPS pIC₅₀, B = DNA T_m and C is an (optional) computed descriptor (selected from 307 descriptors we computed in MOE²⁶). With the UPPS pIC₅₀ and DNA T_m data together, the correlations improved to $R^2 = 0.75$, $p = 0.0001$ for *S. aureus* and $R^2 = 0.53$, $p = 0.007$ for *E. coli*, Table S1. These results improved further with addition of a computed descriptor (vsurf_ID5 for *S. aureus*; GCUT_SMR_3 for *E. coli*) to $R^2 = 0.89$, $p = 6 \times 10^{-6}$ for *S. aureus* and $R^2 = 0.79$, $p = 0.0002$ for *E. coli* (Table S1). The T_m term was the major contributor to the *S. aureus* model while both UPPS inhibition and

DNA binding contributed to the *E. coli* model. The experimental versus computed cell pEC₅₀ results are shown in Figures 4B, C. There was no significant correlation between pIC₅₀ (EcUPPS) and T_m (R² = 0.02, p = 0.6), or between pIC₅₀ (SaUPPS) and T_m (R² = 0.003, p = 0.8) when data for all 16 compounds was used.

These results suggest, then, an extended model for the potent *S. aureus* growth inhibition reported previously⁶ for **1** in which there is multi-target inhibition (DNA binding as well as UPPS inhibition), consistent with the observed synergistic interaction seen with meticillin in a meticillin-resistant strain of *S. aureus*, as illustrated schematically in Figure 5.

X-ray structures of SaUPPS and EcUPPS: progress and puzzles

Finally, we sought to investigate how some of the UPPS inhibitors bound to UPPS. The SaUPPS protein was of most interest since inhibitors such as **1** bind tightly to SaUPPS and are active *in vivo*. At present, there have been no reports of the structures of SaUPPS with (or without) inhibitors, although there are two reported structures of SaUPPS with its FPP substrate.^{6,27} Unfortunately, we were not successful in obtaining any bisamidine-bound SaUPPS X-ray structures, but we did obtain the structure of apo-UPPS as well as that of a *S. thiolo* farnesyl diphosphate (FSPP) inhibitor (IC₅₀ = 1.9 μM). Full crystallographic data acquisition and structure refinement details (PDB ID codes 3WYI, 4U82) are given in Table 3. Ligand electron density maps and ligand-protein interactions are given in Supporting Information Figures S5 and S6. The apo-SaUPPS structure (Figure 6A) has a 1.4 Å Cα residue mean square deviation (rmsd) from the EcUPPS apo structure (PDB ID code 3QAS), while the FSPP-SaUPPS structure (Figure 6B) has a 1.1 Å rmsd from the FSPP-EcUPPS structure (PDB ID code 1X06). These two proteins have a 43% sequence identity and 62% similarity as calculated by BLAST analysis.²⁸ These strong sequence and structural similarities suggest that SaUPPS bisamidine inhibitors should bind in a similar manner to that seen with EcUPPS, to i.e. sites 2, 4 as reported previously.⁶ The question then arises as to why we were unsuccessful in obtaining SaUPPS bisamidine-bound structures. One likely possibility is that since in the apo-SaUPPS structure, residues 77–84 (shown in red in Figure 6A, B) form a loop that blocks entrance to the binding pocket, at least in the crystal. In the FSPP-inhibitor structure, the loop is displaced, as shown in Figure 6C, D, and FSPP, Mg²⁺ and sulfate are clearly visible. The molecular basis for this pocket closure in the apo form is not obvious, but may simply be due to lattice packing effects (since both SaUPPS and EcUPPS are inhibited by bisamidines, in solution). The inability to obtain a bisamidine-bound SaUPPS structure was also reflected in our inability to obtain a structure with another large inhibitor **19**, consistent with a lattice-packing effect (since **19** is also a good SaUPPS inhibitor, in solution). We did succeed, however, in obtaining a structure of **19** bound to EcUPPS, Figure 7.

As reported previously,²⁹ small bisphosphonates bind to EcUPPS with their lipophilic side-chains binding to one or more of sites 1, 2, 3 or 4,²⁹ as shown for the inhibitor BPH-629 ([2-(3-(dibenzofuran-2-yl-phenyl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid) in Figure 7A. However, with the bisamidine **14** (Figure 7B) as well as the diacetylenic amine species **18** (which would be expected to protonated), only a single molecule bound to UPPS, and these molecules were found to span both sites 2 and 4, the cationic groups being relatively

solvent exposed, while the aromatic groups were buried in the hydrophobic interior of the protein. With **19**, we found that sites 1–3 were all occupied, Figure 7C. Full crystallographic data acquisition and structure refinement details (PDB ID code 3WYJ) are given in Table 3. Ligand electron density maps and ligand-protein interactions are given in Supporting Information Figure S7–8.

Conclusions

The results we have reported here are of interest for a number of reasons. First, we synthesized and tested a range of amidine and bisamidine compounds against *E. coli* and *S. aureus* UPPS finding quite potent activity with some bisamidines. Second, we found that several bisamidines also bound to AT-rich DNA, shifting T_m by as much as 24 °C. Third, we developed computational models for cell growth inhibition using DNA T_m and UPPS pIC_{50} values together with one mathematical descriptor that had $R^2 = 0.79$ – 0.89 . Fourth, we determined the structures of 3 bisamidines bound to a synthetic DNA (CGCGAATTTCGCG)₂ finding minor groove binding, with the largest T_m correlating with the largest number of ligand-DNA interactions. Fifth, we solved three UPPS structures. Overall, the most important finding is that the compounds with best cell growth inhibition bind to AT-rich DNA in addition to inhibiting UPPS. This is a potentially important observation since it could lead to novel therapeutic leads that inhibit bacterial cell wall biosynthesis (targeting UPPS), synergize with existing drugs acting in these pathways (as does **1** with meticillin in a meticillin-resistant *S. aureus* strain), and also inhibit DNA replication: multiple-targeting leads that could in some cases help reverse resistance. It is, however, also possible that there may be toxicity against a potential host with such multi-target inhibitors although EC_{50} values against mammalian cells (manuscript in preparation) for compound **1** are $>100 \mu M$, leading to selectivity indices with *S. aureus* of >300 . Moreover, **1** showed no adverse side-effects in the *S. aureus* mouse model of infection⁶ and **7** and **8** have been reported to be effective in mice models of infection with both *Bacillus anthracis* as well as *Yersinia pestis*.¹¹

Experimental section

Chemical Syntheses: General Methods

All chemicals were reagent grade. Pentamidine and netropsin were purchased from Aldrich. ¹H NMR and ¹³C NMR spectra were obtained on Varian (Palo Alto, CA) Unity spectrometers at 400 and 500 MHz for ¹H and at 100 and 125 MHz for ¹³C. Elemental analyses were carried out in the University of Illinois Microanalysis Laboratory. HPLC/MS analyses were performed by using an Agilent LC/MSD Trap XCT Plus system (Agilent Technologies, Santa Clara, CA) with an 1100 series HPLC system including a degasser, an autosampler, a binary pump, and a multiple wavelength detector. All final compounds were 95% pure as determined by elemental analysis or analytical HPLC/MS analysis and were also characterized by ¹H NMR and HRMS.

N4,N4'-bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-[1,1'-biphenyl]-4,4'-bicarboxamide (1)—To a mixture of 4,4'-diphenyl dicarbonyl chloride (1.39 g, 5 mmol), 3-aminobenzonitrile (1.18 g, 10 mmol) in anhydrous THF (20 mL) was added Et₃N (2.1 mL,

15 mmol) and the mixture stirred at room temperature overnight. After filtration, the white solid was washed with water (20 mL) and ethyl acetate (10 mL) and then dried. Sodium hydrosulfide hydrate (100 mg), ethylenediamine (2 mL), and dimethylacetamide (10 mL) were then added and stirred overnight at 140 °C. Upon solvent removal, the solid was washed thoroughly with water and then ethyl acetate (10 mL). To a suspension of the crude product in 10 mL of water were added two equivalents of methanesulfonic acid. Removal of water afforded the final product **1** as its methanesulfonic acid salt (1.44 g, 40%). ¹H NMR (DMSO-*d*₆, 500 MHz) δ: 10.68 (s, 2 H), 10.52 (s, 4 H), 8.50 (s, 2 H), 8.12 (d, *J* = 9.0 Hz, 4 H), 8.02–7.98 (m, 2 H), 7.96 (d, *J* = 9 Hz, 4 H), 7.68–7.58 (m, 4 H), 4.00 (s, 8 H), 2.36 (s, 6 H). HRMS (ESI): *m/z* [M + H]⁺ calculated for C₃₂H₂₉N₆O₂ 529.2361, found 529.2352. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 μm, 300 nm, retention time = 5.6 min): 98.9%.

1,4-bis(6-(1,4,5,6-tetrahydropyrimidin-2-yl)-1*H*-indol-2-yl)benzene (6)—

Terephthalaldehyde (1.34 g, 10 mmol) and 4-methyl-3-nitrobenzonitrile (3.24 g, 20 mmol) were added to a round-bottom flask and heated to 150 °C until the compounds melted. Piperidine (1.5 mL) and sulfolane (10 mL) were added and the resulting solution stirred at 150 °C overnight then cooled to room temperature to yield an orange solid (3.4 g, 80%) which was washed with methanol (15 mL ×3) and dried. The solid, 4,4'-(1*E*,1'*E*)-2,2'-(1,4-phenylene)bis(ethene-2,1-diyl)bis(3-nitrobenzonitrile) was then suspended in triethyl phosphate (30 mL) and heated to reflux (160 °C) for 72 h until the mixture turned from orange to yellow. The suspension was filtered and the yellow solid washed with methanol (15 mL ×3) and dried (1.4 g, 55%). The solid 2,2'-(1,4-phenylene)bis(1*H*-indole-6-carbonitrile) was suspended in propane-1,3-diamine (15 mL) and heated to 130 °C for 24 h. The suspension was filtered and the solid washed with water (15 mL ×3) and methanol (15 mL ×3). The final product **6** was a yellow solid. ¹H NMR (DMSO-*d*₆, 500 MHz) δ: 7.99 (s, 4 H), 7.79 (s, 2 H), 7.48 (d, *J* = 8.0 Hz, 2 H), 7.42 (d, *J* = 8.0 Hz, 2 H), 6.99 (s, 2 H), 3.37 (s, 8 H), 1.72 (m, 4 H). HRMS (ESI): *m/z* [M + H]⁺ calculated for C₃₀H₂₉N₆ 473.2454, found 473.2450. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 μm, 230 nm, retention time = 5.8 min): 99.1%.

1,4-bis(6-(4,5-dihydro-1*H*-imidazol-2-yl)-1*H*-indol-2-yl)benzene (7)—

Terephthalaldehyde (1.34 g, 10 mmol) and 4-methyl-3-nitrobenzonitrile (3.24 g, 20 mmol) were added to a round-bottom flask and heated to 150 °C until the compounds melted. Piperidine (1.5 mL) and sulfolane (10 mL) were added and the resulting solution stirred at 150 °C overnight then cooled to room temperature to yield an orange solid (3.4 g, 80%) which was washed with methanol (15 mL ×3) and dried. The solid 4,4'-(1*E*,1'*E*)-2,2'-(1,4-phenylene)bis(ethene-2,1-diyl)bis(3-nitrobenzonitrile) was then suspended in triethyl phosphate (30 mL) and heated to reflux (160 °C) for 72 h until the mixture turned from orange to yellow. The suspension was then filtered and the yellow solid washed with methanol (15 mL ×3) and dried (1.4 g, 55%). The solid 2,2'-(1,4-phenylene)bis(1*H*-indole-6-carbonitrile) was suspended in ethane-1,2-diamine (15 mL) and heated to 130 °C for 24 h. The suspension was filtered and the solid washed with water (15 mL ×3) and methanol (15 mL ×3). The final product **7** was a yellow solid. ¹H NMR (DMSO-*d*₆, 500 MHz) δ: 11.73 (s, 2 H), 7.97 (s, 4 H), 7.85 (s, 2 H), 7.50 (s, 4 H), 7.00 (s, 2 H), 3.28 (s, 4 H). HRMS (ESI):

m/z $[M + H]^+$ calculated for $C_{28}H_{25}N_6$ 445.2141, found 445.2139. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 μ m, 230 nm, retention time = 5.5 min): 99.3%.

1*H*-Indole, 2,2'-(1,2-ethenediyl)bis[6-(4,5-dihydro-1*H*-imidazol-2-yl)

dihydrochloride (8)—The compound was obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute. 1H NMR (methanol- d_4 , 400 MHz): 7.92 (s, 2H), 7.71 (d, 8.4 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 7.33 (s, 2H), 6.78 (s, 2H), 4.08 (s, 4H). HRMS (ESI): m/z $[M + H]^+$ calculated for $C_{24}H_{23}N_6$ 395.1984, found 395.1986. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 μ m, 230 nm, retention time = 5.6 min): 97.2%.

N4,N4'-bis(3-(1,4,5,6-tetrahydropyrimidin-2-yl)phenyl)biphenyl-4,4'-

dicarboxamide (10)—To a mixture of 4,4'-diphenyl dicarbonyl chloride (1.39 g, 5 mmol), 3-aminobenzonitrile (1.18 g, 10 mmol) in anhydrous THF (20 mL) was added Et_3N (2.1 mL, 15 mmol) and the mixture stirred at room temperature, overnight. After filtration, the white solid was washed with water (20 mL) and ethyl acetate (10 mL) and then dried. Sodium hydrosulfide hydrate (100 mg), propane-1,3-diamine (2 mL), and dimethylacetamide (10 mL) were then added and the mixture stirred overnight at 140 °C. Upon solvent removal, the solid was washed with water and then ethyl acetate (10 mL). To the suspension of the crude product in 10 mL of water were added two equivalents of methanesulfonic acid. Removal of water afforded the final product as its methanesulfonic acid salt (1.50 g, 40%). 1H NMR (DMSO- d_6 , 500 MHz) δ : 10.68 (s, 2 H), 9.95 (s, 4 H), 8.38 (s, 2 H), 8.14 (d, J = 9.0 Hz, 4 H), 7.98 (m, 6 H), 7.62 (t, 2 H), 7.42 (d, 2 H), 3.50 (s, 8 H), 2.29 (s, 4 H). HRMS (ESI): m/z $[M + H]^+$ calculated for $C_{34}H_{33}N_6O_2$ 557.2665, found 557.2658. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 μ m, 230 nm, retention time = 5.3 min): 99.6%.

N4,N4'-bis(3-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl)biphenyl-4,4'-

bis(carbothioamide) (11)—N4,N4'-bis(3-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl)-[1,1'-biphenyl]-4,4'-bicarboxamide (**1**, 560 mg, 1 mmol) was suspended in pyridine (5 mL). Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide) (1.0 g, 2.5 mmol) was added and the mixture heated to 150 °C for 72 h at which point the mixture had turned yellow. The suspension was then filtered and the solid washed with methanol (15 mL ×3) and acetone (15 mL ×3) and then dried under vacuum. The product **11** was obtained as a yellow solid. 1H NMR (DMSO- d_6 , 500 MHz) δ : 12.12 (s, 2 H), 10.60 (s, 4 H) 8.45 (s, 2 H), 7.90 (d, J = 9.0 Hz, 4 H), 8.00–7.98 (m, 2 H), 7.82 (d, J = 9 Hz, 4 H), 7.73 (m, 4 H), 4.00 (s, 8 H). HRMS (ESI): m/z $[M + H]^+$ calculated for $C_{32}H_{29}N_6S_2$ 561.1895, found 561.1896. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 μ m, 230 nm, retention time = 5.8 min): 97.6%.

N⁴-(3-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl)-N^{4'}-(3-(((2*S*,3*R*,4*S*,5*S*,6*R*)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yl)oxy)phenyl)-[1,1'-biphenyl]-4,4'-dicarboxamide (12)—

3-nitrobenzonitrile (3.6 g, 20 mmol) was treated with ethylene diamine (40 mL) and NaHS (200 mg). The solution was heated at 110 °C for 48 h and then quenched with water. The residue was extracted with ethyl acetate, dried under vacuum and purified by flash chromatography (silica gel, hexane/ethyl acetate = 2/1) to give the dihydroimidazole compound **12a** (2.6 g, 60%). To a solution of **12a** (2.2 g, 10 mmol) and NaHCO₃ (3.6 mg, 40 mmol) in dichloromethane (20 mL) and water (20 mL) was added (Boc)₂O (4.5 g, 20 mmol) with vigorous stirring at 0 °C. Stirring was continued for 12 h at which point the mixture had to room temperature. The dichloromethane phase was separated and concentrated to give the Boc protected nitro compound. To the Boc protected nitro compound in ethyl acetate (40 mL) was added Pd/C (10% palladium on charcoal, 145 mg) under nitrogen at room temperature. The nitrogen was switched to H₂ using a balloon and stirring was continued for 12 h at room temperature. Filtration and concentration under reduced pressure gave the 3-aminophenyl imidazoline **12b**. Glucose tetraacetate (3.5 g, 10 mmol) was treated with trichloroacetonitrile (14.4 g, 100 mmol), DBU (0.3 g, 2 mmol) and CH₂Cl₂ (40 mL). The solution was stirred at room temperature for 12 h and then washed with water. The residue was extracted with Et₂O, dried under vacuum and purified by flash chromatography (silica gel, hexane/ethyl acetate = 2/1) to give the peracetyl glucopyranosyl trichloroacetimidate **12c** (4.4 g, 90%). A mixture of **12c** (4.0 g, 8 mmol), 3-nitrophenol (1.1 g, 8 mmol), and freshly activated 4 Å molecular sieves in anhydrous CH₂Cl₂ (30 mL) was stirred under N₂ at 0 °C for 10 min, then BF₃•Et₂O (40 µL, 0.8 mmol) was added via syringe. Stirring continued for 3 h, then Et₃N (2 mL) was added, and the resulting mixture filtered through Celite. The filtrate was concentrated and purified by silica gel column chromatography (hexane/ethyl acetate = 3/1) to give 3-nitrophenol glycoside **12d** (3.0 g, 80%). To a solution of **12d** (2.3 g, 5 mmol) in ethyl acetate (20 mL) was added Pd/C (10% palladium on charcoal, 100 mg) under nitrogen at room temperature. The nitrogen was switched to H₂ using a balloon and stirring was continued for 12 h at room temperature. Filtration and concentration under reduced pressure gave 3-aminophenol glycoside **12e**. To a solution of **12b** (520 mg, 2 mmol), **12e** (920 mg, 2 mmol) and Et₃N (1 mL) in dry

dichloromethane (20 mL) was added [1,1'-biphenyl]-4,4'-dicarbonyl dichloride (560 mg, 2 mmol) at 0 °C. Stirring was continued for 4 h at 0 °C. The reaction mixture was washed with water (15 mL × 3), then concentrated under reduced pressure to give the residue. Purification of the residue by chromatography (silica gel, hexane/ethyl acetate = 2/1) gave product **12f** (800 mg, 45%). To a solution of **12f** (450 mg, 0.5 mmol) in MeOH (5 mL) was added MeONa (1 g) at room temperature. Stirring was continued for 4 h at room temperature and all the volatile components were removed under reduced pressure. The resulting residue was purified by chromatography (silica gel, ethyl acetate) to give the non-protected glycoside. To a solution of the free glycoside (360 mg, 0.5 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (2 mL) with stirring at room temperature. Stirring was continued for 4 h then all volatile components were removed under reduced pressure. The resulting residue was purified by chromatography (silica gel, chloroform/MeOH = 5/1) to give the final product **12** (340 mg, 95%). ¹H NMR (methanol-*d*₄, 400 MHz) 8.48 (m, 1H), 8.06 (m, 4H), 7.96 (m, 5H), 7.61 (m, 2H), 7.55 (m, 1H), 7.37 (d, *J* = 8.0 Hz, 1H), 7.26 (t, *J* = 8.0 Hz, 1H), 6.89 (dd, *J* = 1.6 Hz, 1H), 4.78 (s, 1H), 4.11 (s, 4H), 3.90 (dd, *J* = 12.0, 2.0 Hz, 1H), 3.71 (dd, *J* = 12.0, 7.6 Hz, 1H), 3.46–3.38 (m, 5H). HRMS (ESI): *m/z* [M + H]⁺ calculated for C₃₅H₃₅N₄O₈, 639.2455; found 639.2446. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A, 100×2 mm, 3 μm, 210 nm, retention time = 5.8 min): 97.9%.

***N*⁴-(3-(4,5-dihydro-1*H*-imidazol-2-yl)phenyl)-*N*^{4'}-(3-methoxyphenyl)-[1,1'-biphenyl]-4,4'-dicarboxamide (**13**)—**

3-nitrobenzonitrile (3.6 g, 20 mmol) was treated with ethylene diamine (40 mL) and NaHS (200 mg). The solution was heated at 110 °C for 48 h and then quenched with water. The residue was extracted with ethyl acetate, dried under vacuum and purified by flash chromatography (silica gel, hexane/ethyl acetate = 2/1) to give the dihydroimidazole compound **13a** (2.6 g, 60%). To a solution of **13a** (2.2 g, 10 mmol) and NaHCO₃ (3.6 mg, 40 mmol) in dichloromethane (20 mL) and water (20 mL) was added (Boc)₂O (4.5 g, 20 mmol) with vigorous stirring at 0 °C. Stirring was continued for 12 h at which point the mixture had risen to room temperature. The dichloromethane phase was separated and concentrated to give the Boc protected nitro compound. To a solution of the Boc protected nitro compound in ethyl acetate (40 mL) was added Pd/C (10% palladium on charcoal, 145 mg) under nitrogen at room temperature. The nitrogen was switched to H₂ using a balloon and stirring continued for 12 h at room temperature. Filtration and concentration under reduced pressure gave the crude 3-aminophenyl imidazoline **13b**. To a solution of **13b** (260 mg, 1 mmol), 3-methoxyaniline (120 mg, 1 mmol) and Et₃N (0.5 mL) in dry

dichloromethane (10 mL) was added [1,1'-biphenyl]-4,4'-dicarbonyl dichloride (280 mg, 1 mmol) at 0 °C. Stirring was continued for 4 h at 0 °C then the reaction mixture was washed with water (5 mL × 3), and concentrated under reduced pressure. Purification of the residue by chromatography (silica gel, hexane/ethyl acetate = 2/1) gave the product **13c** (240 mg, 42%). To a solution of **13c** (115 mg, 0.2 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (1 mL) with stirring at room temperature. Stirring was continued for 4 h and all the volatile components were removed under reduced pressure. The resulting residue was purified by chromatography (silica gel, chloroform/MeOH = 5/1) to give the final product **13** (112 mg, 95%). ¹H NMR (methanol-*d*₄, 400 MHz) 8.45 (s, 1H), 8.03 (m, 4H), 7.90–7.80 (m, 6H), 7.59 (m, 2H), 7.30 (m, 1H), 6.71 (m, 1H), 4.09 (s, 4H), 3.78 (s, 3H). HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₃₀H₂₇N₄O₃, 491.2083; found 491.2084. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A, 100×2 mm, 3 μm, 280 nm, retention time = 6.5 min): 97.5%.

N',N'-bis(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-2-nitroterephthalamide dihydrochloride (14)—The compound was obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute. ¹H NMR (methanol-*d*₄, 400 MHz), 8.78 (d, *J* = 1.6 Hz, 2H), 8.42 (d, *J* = 8.0 Hz, 1H), 8.07 (dd, *J* = 8.8 Hz, 2H), 7.95–7.87 (m, 9H), 4.08 (s, 8H). HPLC-MS: *m/z* [M + H]⁺ calculated for C₂₆H₂₄N₇O₄, 498.1890; found 498.1882. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A, 100×2 mm, 3 μm, 280 nm, retention time = 5.0 min): 95.2%.

(2S,3R,4S,5S,6R)-2-(3-((4-((3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)ethynyl)phenyl)ethynyl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (15)—

Glucose tetraacetate (3.5 g, 10 mmol) was treated with trichloroacetonitrile (14.4 g, 100 mmol), DBU (0.3 g, 2 mmol) and CH₂Cl₂ (40 mL). The solution was stirred at room temperature for 12 h and then washed with water. The residue was extracted with Et₂O, dried under vacuum and purified by flash chromatography (silica gel, hexane/ethyl acetate = 2/1) to give the peracetyl glucopyranosyl trichloroacetimidate **15a** (4.4 g, 90%). A mixture of **15a** (4.0 g, 8 mmol), 3-bromophenol (1.4 g, 8 mmol), and freshly activated 4 Å molecular sieves in anhydrous CH₂Cl₂ (30 mL) was stirred under N₂ at 0 °C for 10 min, then BF₃Et₂O (40 μL, 0.8 mmol) was added through a syringe. Stirring continued for 3 h, Et₃N (2 mL) was added, and the resulting mixture filtered through Celite. The filtrate was concentrated and the residue purified by silica gel column chromatography (hexane/ethyl acetate = 3/1) to

give 3-bromophenol glycoside **15b** (3.2 g, 80%). 3-bromobenzonitrile (1.8 g, 10 mmol) was treated with ethylene diamine (20 mL) and NaHS (100 mg). The solution was heated at 110 °C for 48 h and then quenched with water. The residue was extracted with ethyl acetate, dried under vacuum and purified by flash chromatography (silica gel, hexane/ethyl acetate = 2/1) to give the dihydroimidazole compound **15c** (1.3 g, 60%). To a solution of **15c** (440 mg, 2 mmol) and NaHCO₃ (710 mg, 8 mmol) in dichloromethane (6 mL) and water (6 mL) was added (Boc)₂O (900 mg, 4 mmol) with vigorous stirring at 0 °C. Stirring was continued for 12 h at which point the temperature had risen to room temperature. The dichloromethane phase was separated and concentrated to give the Boc protected product **15d**. To a solution of 1,4-diethynylbenzene (66 mg, 0.5 mmol), **15b** (500 mg, 1.0 mmol) and **15d** (320 mg, 1.0 mmol) in toluene (freshly distilled from sodium, 3 mL) was added CuI (4 mg, 0.03 mmol), Pd(PPh₃)₄, then Et₃N (82 µL, 0.5 mmol) under an N₂ atmosphere. Stirring was continued for 4 h at 60 °C. Purification with flash chromatography (silica gel, hexane/ethyl acetate = 3/1) gave the coupling product **15e** (80 mg, yield: 20%). To a solution of **15e** (80 mg, 0.1 mmol) in MeOH (1 mL) was added MeONa (0.3 g) at room temperature. Stirring was continued for 4 h at room temperature, then all volatile components were removed under reduced pressure. The residue was purified by chromatography (silica gel, ethyl acetate) to give the Boc-protected glycoside. To a solution of the Boc-protected glycoside (64 mg, 0.1 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.2 mL) with stirring at room temperature. Stirring was continued for 4 h then all the volatile components were removed under reduced pressure. The resulting residue was purified by chromatography (silica gel, chloroform/MeOH = 5/1) to give the final product **15** (60 mg, 95%). ¹H NMR (methanol-*d*₄, 400 MHz) 8.03 (s, 1H), 7.90 (d, 1H), 7.81 (d, 1H), 7.66 (m, 1H), 7.55 (s, 4H), 7.33–7.10 (m, 4H), 4.12 (s, 4H), 3.90–3.45 (m, 4H). HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₃₁H₂₉N₂O₆, 525.2026; found 525.2018. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 µm, 250 nm, retention time = 6.1 min): 98.9%.

N⁴-(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-N^{4'}-(3-(hexyloxy)phenyl)-[1,1-biphenyl]-4,4'-dicarboxamide (16)—Compound **16** was made by using the same protocol as described for **13**. ¹H NMR (methanol-*d*₄, 400 MHz) 8.48 (s, 1H), 8.05 (m, 4H), 7.85 (m, 5H), 7.61 (m, 2H), 7.40 (s, 1H), 7.23 (m, 2H), 6.70 (m, 1H), 4.11 (s, 4H), 3.97 (t, *J* = 6.0 Hz, 2H), 1.77 (m, 2H), 1.48 (m, 2H), 1.36 (m, 4H), 0.91 (t, *J* = 6.8 Hz, 3H). HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₃₅H₃₇N₄O₃, 561.2866; found 561.2875. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 µm, 280 nm, retention time = 7.2 min): 97.9%.

N⁴-(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)-N^{4'}-(3-phenoxyphenyl)biphenyl-4,4'-dicarboxamide (17)—Compound **17** was made by using the same protocol as described for **13**. ¹H NMR (methanol-*d*₄, 400 MHz) 8.47 (d, *J* = 1.6 Hz, 1H), 8.07 (d, *J* = 8.4 Hz, 2H), 8.01 (d, *J* = 8.4 Hz, 2H), 7.90–7.81 (m, 5H), 7.6 (m, 2H), 7.48 (s, 1H), 7.44 (d, *J* = 12.4 Hz, 1H), 7.37–7.30 (m, 3H), 7.11 (t, *J* = 7.6 Hz, 1H), 7.03 (s, 1H), 7.01 (s, 1H), 6.77 (t, *J* = 8.0, 1.2 Hz, 1H), 4.11 (s, 4H). HRMS (ESI): *m/z* [M + H]⁺ Calcd for C₃₅H₂₉N₄O₃, 553.2240; found 553.2249. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A. 100×2 mm, 3 µm, 210 nm, retention time = 6.3 min): 99.8%.

2,2'-(5,5'-(1,3-phenylenebis(ethyne-2,1-diyl))bis(3-bromo-5,1-phenylene))diethanamine (18)—

To a solution of 3,5-dibromobenzyl alcohol (1.06 g, 4 mmol) in dichloromethane (15 mL) was added Ph_3P (1.31 g, 5 mmol), then NBS (890 mg, 5 mmol) at 0 °C. Stirring was continued for 3 h at 0 °C then all volatile components were removed under reduced pressure. Purification with flash chromatography (silica gel, hexane) gave dibromobenzyl bromide (760 mg, yield: 85%). To a solution of dibromobenzyl bromide (700 mg, 2.13 mmol) in DMF (10 mL) was added KCN (277 mg, 4.26 mmol). The mixture was stirred at 80 °C for 15 h. The reaction mixture was separated between ethyl acetate and water after it cooled to room temperature. The ethyl acetate phase was evaporated under reduced pressure to give the nitrile product **18a**. To a solution of **18a** in dry Et_2O (10 mL) was added LiAlH_4 (74 mg, 2 mmol). The reaction was quenched with NH_4OH (37% in water, 1 mL) after stirring for 2 h at room temperature. The diethyl ether phase was dried over anhydrous Na_2SO_4 then solvent removed under reduced pressure to give the crude amine. To a suspension of the crude amine and NaHCO_3 (504 mg, 6 mmol) in a two phase solution (dichloromethane/water, 1/1 v/v, 20 mL) was added $(\text{Boc})_2\text{O}$ (872 mg, 4 mmol). Vigorous stirring was continued at room temperature for 12 h. The dichloromethane phase was separated, dried over anhydrous Na_2SO_4 , then solvents removed under reduced pressure and the product purified by flash chromatography (silica gel, hexane/ethyl acetate = 10/1) to give the Boc-amine **18b** (411 mg, yield: 51% over 3 steps). To a solution of 1,3-diethynylbenzene (33 mg, 0.25 mmol) and **18b** (400 mg, 1.1 mmol) in toluene (freshly distilled from sodium, 3 mL) was added CuI (4 mg, 0.03 mmol), $\text{Pd}(\text{PPh}_3)_4$, then Et_3N (82 μL , 0.5 mmol) under an N_2 atmosphere. Stirring was continued for 4 h at 60 °C. Purification with flash chromatography (silica gel, hexane/ethyl acetate, 5/1 v/v) gave product **18c** (63 mg, yield: 35%). 40 mg of **18c** was then added to a 1/1 v/v solution of trifluoroacetic acid/dichloromethane at room temperature. Stirring was continued for 10 min. Purification with flash chromatography (silica gel, chloroform/MeOH, 10/1 v/v) after removing all the volatile components gave the product **18** (26 mg, yield: 62%). ^1H NMR ($\text{DMSO}-d_6$, 500 MHz) δ : 7.66–7.42 (m, 10 H), 3.19(t, J = 8.0 Hz, 4 H), 2.95 (t, J = 8.0 Hz, 4 H) ppm. HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{26}\text{H}_{23}\text{Br}_2\text{N}_2$, 521.0228; found 521.0214. Purity of the product determined by HPLC (Phenomenex C6-Phenyl 110A, 100 $\times$ 2 mm, 3 μm , 280 nm, retention time = 6.4 min): 96.5%.

[1-Hydroxy-2-(3-{3-[3-(2-hydroxy-2,2-bis-phosphono-ethyl)-biphenyl-3-ylsulfamoyl]-benzenesulfonylamino}-biphenyl-3-yl)-1-phosphono-ethyl] - phosphonic acid (19)—

To a solution of methyl 2-(3-bromophenyl) acetate (2.3 g, 10 mmol) and 3-aminophenyl boronic acid (2.1 g, 15 mmol) in toluene was added Pd(PPh₃)₄ (260 mg, 1 mmol) and K₂CO₃ (2.8 g, 20 mmol). The solution was heated at 100 °C for 24 h then quenched with water. The biphenyl product **19a** was extracted with ethyl acetate (30 mL ×3) and the organic layers combined and solvents removed under vacuum. The residue was purified with flash column chromatography to yield **19a** (1.6 g, 66%). Compound **19a** (1.2 g, 5 mmol) was then treated with benzene-1,3-disulfonyl dichloride (1.5 g, 5.5 mmol) and triethyl amine (2 mL) and CH₂Cl₂ (30 mL) under nitrogen and the solution stirred at room temperature for 12 h followed by washing with water and drying under vacuum to yield **19b** (3.3 g, 95%), which was utilized in next step without further purification. Compound **19b** (1.4 g, 2 mmol) was stirred with LiOH (1 g in 10 mL water) and THF (10 mL) for 4 h and then the solution was neutralized with HCl (6 M). The precipitate was collected with a Buchner funnel and washed with water and acetone. The residue was the crude acid product **19c** (1.3 g, 95%) and was used in next step without further purification. The acid **19c** (1.3 g, 2 mmol) was treated with (COCl)₂ (1 mL) in the presence of CH₂Cl₂ (20 mL) and DMF (1 drop). The mixture was stirred under nitrogen at room temperature for 10 h then dried under vacuum to give the acyl chloride **19d** (1.4 g, 99%) which was used in next step without purification. The acyl chloride **19d** (1.4 g, 2 mmol) was treated with tris(trimethylsilyl) phosphate (0.6 g, 4 mmol) and THF (20 mL) and the mixture stirred at room temperature for 1 h to yield intermediate **19e** which was then treated with methanol and stirred at room temperature for 1 h to give the final product **19** (1.2 g, 60%). ¹H NMR (D₂O, 500 MHz) 8.05 (s, 1H), 7.70 (m, 2H), 7.42–6.83 (m, 15H), 6.52 (m, 2H), 3.35 (m, 2H), 2.90 (m, 4H). Microchemical analysis (C, H, N): calculated: 38.87% (C), 3.55% (H), 2.67% (N); Found: 38.48% (C), 3.93% (H), 2.9% (N).

Protein Expression, Purification and Inhibition

EcUPPS and SaUPPS were expressed and purified as described previously.⁶ UPPS inhibition assays were also carried out as described previously.⁶ Briefly, the condensation of FPP with IPP catalyzed by UPPS was monitored by using a continuous spectrophotometric assay³⁰ in 96 well plates with 200 μL reaction mixtures containing 400 μM MESG, 25 μM IPP, 2.5 μM FPP, 25 μM Tris-HCl (pH 7.5), 0.01% Triton X-100 and 1 mM MgCl₂. The IC₅₀ values were obtained by fitting the inhibition data to a rectangular hyperbolic dose-response function in GraphPad PRISM 4.0 software (Graphpad Software, San Diego, CA).

Cell Growth Inhibition Assay

The growth of *E. coli* (K12) and determination of EC₅₀ values were carried out as described previously.³¹ EC₅₀ values for *S. aureus* growth inhibition were also determined as described previously.³² Briefly, an overnight culture of *S. aureus* (Newman strain) was diluted 50-fold into fresh TSB (tryptic soy broth) and grown for 1 h at 37 °C and then diluted 100-fold into fresh TSB medium. 100 µL aliquots were inoculated into each well of a 96-round-bottom culture plate (Corning Inc., Corning, NY) containing serially diluted compounds and plates were incubated for 9 h with shaking, at 37 °C. Absorbances were measured at 600 nm and dose-response curves constructed using GraphPad PRISM 4.0 software (Graphpad Software, San Diego, CA).

Differential Scanning Calorimetry

The DNA dodecamer (CGCGAATTCGCG)₂ was purchased from Integrated DNA Technologies, Inc. (Coralville, Iowa). DNA and ligand solutions were prepared in Mes buffer (0.01 M Mes, pH 6.2, 0.001 M EDTA, 0.2 M NaCl). All ligand solutions were prepared by adding appropriate amounts of compound powder into a 0.1 mM DNA solution, the final compound concentrations being 0.1 mM. DSC experiments were performed by using a Microcal VP-DSC instrument. The scans covered the 30 to 110 °C range at a rate of 90 °C/h. DSC thermograms were analyzed by using Origin 7.1 software (OriginLab Corporation, Northampton, MA). Buffer vs. buffer scans were used for baseline corrections.

X-Ray Crystallography

Native *E. coli* UPPS crystals (prepared as described previously²⁹) for use in soaking were obtained by using the hanging-drop method kits from Hampton Research, Laguna Niguel, CA by mixing 2 µL of UPPS solution with 2 µL of mother liquor (20% ethylene glycol and 2–5% PEG 35K) and then equilibrating with 500 µL mother liquor at room temperature. Orthorhombic crystals appeared in 2 days and were then soaked in a cryoprotectant solution (30% ethylene glycol and 5% PEG 35K) containing 5 mM inhibitors, for 3 h. Native *S. aureus* UPPS crystals (*apo*-structure) were obtained by using the hanging-drop method by mixing 2 µL of UPPS solution (25 mM Tris-HCl, pH 7.5 and 150 mM NaCl) with 2 µL of mother liquor (100 mM HEPES, pH 6.5, 200 mM MgCl₂, 200 mM NiCl₂ and 20% PEG3350) and then equilibrating with 500 µL mother liquor at room temperature. Crystals appeared in 2 days and were then soaked in a cryoprotectant solution (100 mM HEPES, pH 6.5, 200 mM MgCl₂, 200 mM NiCl₂, 25% PEG3350 and 10% glycerol) for 3 s before data collection. *S. aureus* UPPS crystals with FSPP were obtained by using the hanging-drop method by mixing 1 µL of UPPS solution (~5 mg/ml UPPS in 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1.5 mM MgCl₂, and 1.5 mM FSPP) with 1 µL of mother liquor (100 mM NaMES, pH 6.5, 200 mM (NH₄)SO₄, and 25% PEG MME 5K) and then equilibrating with 400 µL mother liquor at room temperature. Crystals appeared overnight. DNA/ligand complex crystals were obtained via co-crystallization by mixing 0.6 mM dodecamer with the compounds of interest (0.5–5 mM) and left on ice, overnight. These mixtures were then used to grow crystals from hanging drops by mixing 1.5 µL of the mixtures with 1.5 µL of mother liquor (40 mM sodium cacodylate, pH 6.9, 50 mM Mg(OAc)₂ and 6 mM spermine) against a reservoir of 40% MPD. Crystals appeared in about one week.

X-ray diffraction data for *E. coli* UPPS, *S. aureus* UPPS and DNA complexes were collected at the Life Science Collaborative Access Team (LS-CAT) 21-ID-D (G) at the Advanced Photon Source of Argonne National Laboratory, and beamlines 15A1 and 13B1 of the National Synchrotron Radiation Research Center of Taiwan. Diffraction data were processed and scaled by using the program HKL3000 (HKL Research Inc., Charlottesville, VA, USA). Structure refinements were carried out by using Refmac,³³ and Coot.³⁴ All structure figures were prepared by using PyMOL.³⁵ Protein/DNA-ligand interactions were calculated by using PDBsum.³⁶ The statistics for data collection are listed in Tables 2 and 3.

Computational Aspects

All mathematical modeling, heat-map and correlation calculations were performed in R (<http://www.R-project.org>). Mathematical descriptors were calculated by using MOE.²⁶

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENT

This work was supported by the United States Public Health Service (National Institutes of Health grant GM065307); a Harriet A. Harlin Professorship and the University of Illinois/Oldfield Research Fund; the National Basic Research Program of China (grants 2011CB710800 and 2011CBA00805) and the National Natural Science Foundation of China (grants 31200053 and 31300615). We thank Yigui Gao from the University of Illinois Macromolecular Crystallization Laboratory for providing crystallization facilities, and Professor T.E. Kehl-Fie (University of Illinois, Urbana-Champaign) for providing the *S. aureus* Newman strain. We thank the National Synchrotron Radiation Research Center of Taiwan for beam-time allocation and data collection assistance. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract DE-AC02-06CH11357. Use of the Life Science Collaborative Access Team Sector 21 was supported by the Michigan Economic Development Corporation and Michigan Technology Tri-Corridor Grant 085P1000817.

ABBREVIATIONS

UPPS	undecaprenyl diphosphate synthase
FPPS	farnesyl diphosphate synthase
FICI	fractional inhibitory concentration index
FSPP	<i>S-thiolo</i> farnesyl diphosphate
MRSA	meticillin-resistant <i>Staphylococcus aureus</i>
IC₅₀	half maximal inhibitory concentration
EC₅₀	half maximal effective concentration
SaUPPS	<i>Staphylococcus aureus</i> undecaprenyl diphosphate synthase
EcUPPS	<i>Escherichia coli</i> undecaprenyl diphosphate synthase
THF	tetrahydrofuran
TSB	tryptic soy broth
MESG	7-Methyl-6-thioguanosine

IPP	isopentenyl diphosphate
FPP	farnesyl diphosphate
PEG	polyethylene glycol
MME	monomethyl ether
MPD	2-methyl-2,4-pentanediol

REFERENCES

- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. <http://www.cdc.gov/features/AntibioticResistanceThreats/index.html>.
- World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. <http://www.who.int/drugresistance/documents/surveillance/en/>.
- Davies, S.; Grant, J.; Catchpole, M. The drugs don't work: a global threat. Penguin Books Ltd; 2013.
- Durrant JD, Cao R, Gorfe AA, Zhu W, Li J, Sankovsky A, Oldfield E, McCammon JA. Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. *Chem. Bio. Drug Design*. 2011; 78:323–332.
- Lindert S, Zhu W, Liu YL, Pang R, Oldfield E, McCammon JA. Farnesyl diphosphate synthase inhibitors from *in silico* screening. *Chem. Bio. Drug Design*. 2013; 81:742–748.
- Zhu W, Zhang Y, Sinko W, Hensler ME, Olson J, Molohon KJ, Lindert S, Cao R, Li K, Wang K, Wang Y, Liu YL, Sankovsky A, de Oliveira CA, Mitchell DA, Nizet V, McCammon JA, Oldfield E. Antibacterial drug leads targeting isoprenoid biosynthesis. *Proc. Natl. Acad. Sci. USA*. 2013; 110:123–128. [PubMed: 23248302]
- Ashley JN, Barber HJ, Ewins AJ, Newbery G, Self ADH. A chemotherapeutic comparison of the trypanocidal action of some aromatic diamidines. *J. Chem. Soc.* 1942:103–116.
- Fischer, R.; Hirt, R. Carbanilide compounds. US Patent No. 3,622,596. 1971.
- Williams JD, Nguyen ST, Gu S, Ding XY, Butler MM, Tashjian TF, Opperman TJ, Panchal RG, Bavari S, Peet NP, Moir DT, Bowlin TL. Potent and broad-spectrum antibacterial activity of indole-based bisamidine antibiotics: synthesis and SAR of novel analogs of MBX 1066 and MBX 1090. *Bioorgan. Med. Chem.* 2013; 21:7790–7806.
- Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. *Parasites & Vectors*. 2010; 3:15. [PubMed: 20219092]
- Panchal RG, Ulrich RL, Lane D, Butler MM, Houseweart C, Opperman T, Williams JD, Peet NP, Moir DT, Nguyen T, Gussio R, Bowlin T, Bavari S. Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains. *Antimicrob. Agents Chemother.* 2009; 53:4283–4291. [PubMed: 19635954]
- Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL. Comparative *in vitro* activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates. *Antimicrob. Agents Chemother.* 2010; 54:3974–3977. [PubMed: 20625154]
- Opperman, TJ.; Aiello, CHD.; Williams, JD.; Peet, NP.; Moir, DT.; Bowlin, TL. Poster Session, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12–15, 2010; Boston.
- Lanteri CA, Trumpower BL, Tidwell RR, Meshnick SR. DB75, a novel trypanocidal agent, disrupts mitochondrial function in *Saccharomyces cerevisiae*. *Antimicrob. Agents Chemother.* 2004; 48:3968–3974. [PubMed: 15388460]
- Oldfield E, Feng X. Resistance-resistant antibiotics. *Trends in Pharmacol. Sci.* 2014
- Silver LL. Challenges of antibacterial discovery. *Clin. Microb. Rev.* 2011; 24:71–109.
- Wilson WD, Tanious FA, Mathis A, Tevis D, Hall JE, Boykin DW. Antiparasitic compounds that target DNA. *Biochimie*. 2008; 90:999–1014. [PubMed: 18343228]

18. Chai Y, Paul A, Rettig M, Wilson WD, Boykin DW. Design and synthesis of heterocyclic cations for specific DNA recognition: from AT-rich to mixed-base-pair DNA sequences. *J. Org. Chem.* 2014; 79:852–866. [PubMed: 24422528]
19. Barrett MP, Gemmell CG, Suckling CJ. Minor groove binders as anti-infective agents. *Pharmacol. Ther.* 2013; 139:12–23. [PubMed: 23507040]
20. Scott RW, DeGrado WF, Tew GN. *De novo* designed synthetic mimics of antimicrobial peptides. *Curr. Opin. Biotechnol.* 2008; 19:620–627. [PubMed: 18996193]
21. Leon A, Liu L, Yang Y, Hudock MP, Hall P, Yin FL, Studer D, Puan KJ, Morita CT, Oldfield E. Isoprenoid biosynthesis as a drug target: Bisphosphonate inhibition of *Escherichia coli* K12 growth and synergistic effects of fosmidomycin. *J. Med. Chem.* 2006; 49:7331–7341. [PubMed: 17149863]
22. Teng MK, Usman N, Frederick CA, Wang AH. The molecular structure of the complex of Hoechst 33258 and the DNA dodecamer d(CGCGAATTCGCG). *Nuc. Acids Res.* 1988; 16:2671–2690.
23. Nunn CM, Jenkins TC, Neidle S. Crystal structure of d(CGCGAATTCGCG) complexed with propamidine, a short-chain homologue of the drug pentamidine. *Biochem.* 1993; 32:13838–13843. [PubMed: 8268158]
24. Squire CJ, Clark GR, Denny WA. Minor groove binding of a bis-quaternary ammonium compound: the crystal structure of SN 7167 bound to d(CGCGAATTCGCG)₂. *Nuc. Acids Res.* 1997; 25:4072–4078.
25. Mukkamala D, No JH, Cass LM, Chang TK, Oldfield E. Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. *J. Med. Chem.* 2008; 51:7827–7833. [PubMed: 19053772]
26. Molecular Operating Environment (MOE), 2013.08. Montreal, QC, Canada: Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910; 2014. H3A 2R7
27. Ammirati, M.; Pandit, J. Crystal structure of *Staphylococcus* undecaprenyl pyrophosphate synthase and uses thereof. US Patent Application No. 10/688,167. 2002.
28. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nuc. Acids Res.* 1997; 25:3389–3402.
29. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH. Bisphosphonates target multiple sites in both *cis*- and *trans*-prenyltransferases. *Proc. Natl. Acad. Sci. USA.* 2007; 104:10022–10027. [PubMed: 17535895]
30. Webb MR. A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. *Proc. Natl. Acad. Sci. USA.* 1992; 89:4884–4887. [PubMed: 1534409]
31. Li K, Schurig-Briccio LA, Feng XX, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang HL, Rao GD, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren FF, Sun H, Jiang T, Li YJ, Guo RT, Cole ST, Gennis RB, Crick DC, Oldfield E. Multitarget drug discovery for tuberculosis and other infectious diseases. *J. Med. Chem.* 2014; 57:3126–3139. [PubMed: 24568559]
32. Kehl-Fie TE, Zhang Y, Moore JL, Farrand AJ, Hood MI, Rathi S, Chazin WJ, Caprioli RM, Skaar EP. MntABC and MntH contribute to systemic *Staphylococcus aureus* infection by competing with calprotectin for nutrient manganese. *Infect. Immun.* 2013; 81:3395–3405. [PubMed: 23817615]
33. Potterton E, Briggs P, Turkenburg M, Dodson E. A graphical user interface to the CCP4 program suite. *Acta Cryst. Sect. D, Biol. Cryst.* 2003; 59:1131–1137.
34. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Cryst. Sect. D, Biol. Cryst.* 2004; 60:2126–2132.
35. The PyMOL Molecular Graphics System, Version 1.5.0.4. Schrödinger, LLC;
36. de Beer TA, Berka K, Thornton JM, Laskowski RA. PDBsum additions. *Nuc. Acids res.* 2014; 42:D292–D296.

Figure 1.

Structures of compounds of interest, discussed in the Text. Compounds are rank ordered (top left to bottom right) by their effects on the folded-unfolded transition (ΔT_m) of a DNA dodecamer duplex (CGCGAATTTCGCG)₂, as determined by differential scanning calorimetry, the most potent binder being at the top left of the Figure.

Figure 2.

DSC thermograms for the 16 compounds shown in Figure 1 binding to the DNA dodecamer duplex (CGCGAATTCGCG)₂. The T_m values are indicated. Apo-DNA thermograms of are shown in red and DNA/ligand (1:1) thermograms are shown in blue.

Figure 3.

X-ray structures of DNA dodecamer duplex (CGCGAATTCGCG)₂ showing bisamidines bind to minor groove and interact with the nucleobases. (A) **1** (cyan) binds to the DNA minor groove and (B) interacts with A5, A6, C9 and T20 (pink). (C) **6** (yellow) binds to the DNA minor groove and (D) interacts with T7, T8, C9, G10, T19, and T20 (pink). (E) **10** (green) binds to the DNA minor groove and (F) interacts with T8, C9, and A17 (pink). The largest number of bisamidine contacts correlates with the largest T_m value (shown in parentheses).

Figure 4.

Heat-map and correlation plot. (A) Enzyme and cell growth inhibition and DNA binding heat-map. Red = strong activity; yellow = moderate activity; green = weak/no activity. (B) Correlation plot for *S. aureus* experimental and predicted cell activities based on UPPS IC_{50} and DNA T_m results in addition to 1 mathematical descriptor (vsurf_ID5). (C) Correlation plot for *E. coli* experimental and predicted cell activities based on UPPS IC_{50} and DNA T_m results in addition to 1 mathematical descriptor (GCUT_SMR_3).

Author Manuscript

Figure 6.

X-ray structures of *S. aureus* UPSS. (A) Closed structure found in apo-SaUPPS, 77–84 in red (PDB ID code 3WYI). (B) Protein surface representation of apo structure. (C) Ligand bound UPSS showing FSPP, sulfate and Mg²⁺, open pocket, residues 77–84 in red (PDB ID code 4U82). (D) Protein surface representation of FSPP-bound structure.

Figure 7.

X-ray structures of *E. coli* UPPS showing ligand binding sites. (A) The bisposphonate shown binds to sites 1–4 (PDB ID code 2E98). (B) Bisamidine **14** binds to sites 2 and 4 (PDB ID code 4H2J). (C) The tetraphosphonate **19** binds to sites 1–3 (PDB ID code 3WYJ).

Scheme 1.

Structures of bisamidines with anti-infective activity.

Table 1
Enzyme inhibition, cell growth inhibition and differential scanning calorimetry results.

cpd	EcUPPS		SaUPPS		<i>E. coli</i>		<i>S. aureus</i>		T_m (°C)
	IC ₅₀ (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)	EC ₅₀ (μM)	EC ₅₀ (μM)	EC ₅₀ (μM)	EC ₅₀ (μM)	
6	0.68	0.47	0.24	0.028	24				
8	12	5.1	1.2	0.11	20				
7	0.36	1.7	0.33	0.029	16				
9	1400	1000	570	11	16				
1	0.11	0.11	0.30	0.29	11				
10	5.5	4.5	0.66	0.23	10				
11	9.2	3.5	58	3.0	7.1				
12	380	530	>1500	570	5.8				
13	9.4	2.1	570	7.7	5.2				
14	4.8	4.9	14	28	3.9				
3	400	240	12	4.2	2.7				
16	25	8.9	>1500	280	0.7				
17	11	5.7	>1500	10	0.6				
18	9.1	1.4	0.97	7.6	-0.1				
19	0.36	0.39	>1500	100	-1				
15	14	5.6	900	380	-1.2				

Table 2Data collection and refinement statistics for DNA duplex (CGCGAATTCGCG)₂.

	DNA/1	DNA/6	DNA/10
Crystals	(4U8B)	(4U8C)	(4U8A)
Data collection			
Space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁
<i>a</i> , <i>b</i> , <i>c</i> (Å)	23.77, 39.39, 65.36	24.79, 39.95, 65.79	25.18, 40.14, 65.63
Resolution (Å)	50.0–1.31 (1.33–1.31)	50.0–1.24 (1.26–1.24)	50.0–1.48 (1.52–1.48)
No. of reflections	15,205 (731)	18,244 (760)	11,466 (533)
Completeness (%)	98.7 (100.0)	95.0 (83.2)	98.3 (97.1)
<i>R</i> -merge	0.076 (0.66)	0.068 (0.55)	0.050 (0.39)
<i>I</i> /σ(<i>I</i>)	29.8 (5.4)	32.8 (3.6)	44.5 (5.9)
Multiplicity	13.4 (14.3)	13.8 (12.1)	13.8 (12.9)
Refinement statistics			
<i>R</i> -work/ <i>R</i> -free (%)	24.2/24.6	27.6/33.3	26.6/32.2
Geometry deviations			
Bond lengths (Å)	0.019	0.015	0.015
Bond angles (°)	2.76	2.33	2.84
<i>B</i> average (Å ²)/No. of non-H atoms			
DNA	19.7/486	22.8/486	26.1/486
Water	20.2/43	30.5/17	21.6/30
Ligand	39.5/40	26.3/36	22.9/42

Values in parentheses correspond to the highest-resolution shells.

Table 3

Data collection and refinement statistics for UPPS.

	SaUPPS/ <i>Apo</i>	SaUPPS/FSPP	EcUPPS/19
Crystals	(3WYI)	(4U82)	(3WYJ)
Data collection			
Space group	<i>P</i> 3 ₁ 2 ₁	<i>P</i> 4 ₁ 2 ₁ 2	<i>P</i> 2 ₁ 2 ₁ 2 ₁
<i>a</i> , <i>b</i> , <i>c</i> (Å)	62.08, 62.08, 133.49	57.08, 57.08, 158.62	63.71, 69.00, 108.89
Resolution (Å)	25.0–2.0 (2.07–2.00)	50.0–1.66 (1.69–1.66)	25.0–2.1 (2.18–2.10)
No. of reflections	20,923 (2,047)	32,040 (1,573)	28,793 (2,803)
Completeness (%)	100.0 (100.0)	100.0 (99.8)	99.7 (99.7)
<i>R</i> -merge	0.066 (0.50)	0.068 (0.70)	0.049 (0.36)
<i>I</i> /σ(<i>I</i>)	32.8 (3.6)	34.6 (4.6)	39.1 (6.0)
Multiplicity	8.5 (8.2)	14.3 (14.3)	5.8 (5.4)
Refinement statistics			
<i>R</i> -work/ <i>R</i> -free (%)	19.0/22.7	18.7/22.0	20.0/24.1
Geometry deviations			
Bond lengths (Å)	0.015	0.026	0.006
Bond angles (°)	1.20	2.42	1.15
<i>B</i> average (Å ²)/No. of non-H atoms			
Protein	36.1/1894	19.4/1930	36.6/3504
Water	55.4/382	23.7/84	53.6/426
Ligand	-	25.3/25	57.4/60
Ramachandran plot			
Most favored (%)	96.5	97.9	97.2
Allowed (%)	3.5	2.1	2.5
Disallowed (%)	0	0	0.2

Values in parentheses correspond to the highest-resolution shells.